Thus, combining selinexor and venetoclax could be a promising therapeutic approach for MM patients t(11;14) by targeting BCL2 dependency and nuclear export pathways to improve treatment outcomes [20]. The gene discussed is BCL2; the disease is Miyoshi myopathy.